JRSM > Volume 99, Number 3 > Pp. 132-140

This Article Abstract Full Text Full Text (PDF) Send a Quick Comment Alert me when this article is cited Alert me when Quick Comments are posted Alert me if a correction is posted Services Email this article to a friend Related articles in JRSM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Caldwell, B. Articles by Beasley, R. Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis

Brent Caldwell¹ Sarah Aldington¹ Mark Weatherall² Philippa Shirtcliffe¹   Richard Beasley¹

¹ Medical Research Institute of New Zealand, Wellington
² Wellington School of Medicine & Health Sciences, Wellington, New Zealand

View larger version (24K): [in a new window]   Figure 1. Process of inclusion of studies in systematic review. NSAID, non-steroidal anti-inflammatory drug

 

View larger version (6K): [in a new window]   Figure 2. Forest plot of the log of the ratio for risk of myocardial infarction with the use of celecoxib compared to placebo, using the inverse variance weighting method (areas inversely proportional to the variance of the estimate). MI, myocardial infarction

 

View larger version (6K): [in a new window]   Figure 3. Forest plot of the log of the ratio for risk of myocardial infarction with the use of celecoxib compared to all comparator treatments (including placebo, diclofenac, ibuprofen, and paracetamol), using the inverse variance weighting method (areas inversely proportional to the variance of the estimate). MI, myocardial infarction

 

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?